Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

Amivantamab, via its novel mechanism of action, yielded robust and durable responses with tolerable safety in patients with <i>EGFR</i> Exon20ins mutations after progression on platinum-based chemotherapy.